IIM
LGND icon

Ipswich Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

Ipswich Investment Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-40
Closed -$3K – 294
2018
Q4 		$3K Buy
+40
New +$4.26K ﹤0.01% 419
2016
Q2 		– Sell
-802
Closed -$61K – 244
2016
Q1 		$61K Buy
+802
New +$48.7K 0.03% 210

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Ipswich Investment Management's LGND Position: Q1 2019 in Review

Ipswich Investment Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 40 shares — an estimated $3K sold.

Ipswich Investment Management first reported a position in LGND in Q1 2016 and held it in 2 quarters. The position peaked at $61K in Q1 2016. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Ipswich Investment Management reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Ipswich Investment Management sold 40 Ligand Pharmaceuticals shares in Q1 2019, an estimated $3K.
  • Ipswich Investment Management first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Ipswich Investment Management's Ligand Pharmaceuticals position peaked at $61K in Q1 2016.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Ipswich Investment Management's 13F filing for Q1 2019, filed 12 Apr 2019.